Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT Stock Report

Market Cap: US$1.8b

Arcutis Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ARQT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Nov 24BuyUS$21,250Todd WatanabeIndividual6,038US$7.11
30 Nov 24BuyUS$18,543Masaru MatsudaIndividual5,657US$7.11
30 Nov 24BuyUS$7,767Larry EdwardsIndividual1,093US$7.11
19 Nov 24SellUS$17,190Masaru MatsudaIndividual1,775US$9.68
14 Nov 24SellUS$522,436Patrick BurnettIndividual50,749US$10.29
11 Nov 24SellUS$94,238Terrie CurranIndividual8,687US$10.85
04 Nov 24SellUS$134,093Patrick BurnettIndividual15,441US$8.68
04 Nov 24SellUS$43,551Masaru MatsudaIndividual5,015US$8.68
04 Nov 24SellUS$120,459Todd WatanabeIndividual13,871US$8.68
02 Oct 24SellUS$37,295Larry EdwardsIndividual3,725US$10.01
24 Sep 24SellUS$110,264David TopperIndividual11,626US$9.48
03 Sep 24SellUS$107,695Howard WelgusIndividual10,000US$10.77
19 Aug 24SellUS$14,318Patrick BurnettIndividual1,728US$8.29
02 Aug 24SellUS$130,648Todd WatanabeIndividual14,487US$9.02
29 May 24SellUS$435,387Patrick BurnettIndividual49,952US$8.72
28 May 24SellUS$15,988Masaru MatsudaIndividual1,775US$9.01
17 May 24SellUS$68,582Larry EdwardsIndividual7,640US$8.98
02 May 24SellUS$40,902Matthew MooreIndividual4,681US$8.74
04 Mar 24BuyUS$199,994Frazier Life Sciences Management, LPCompany21,052US$9.50
04 Mar 24SellUS$38,568Matthew MooreIndividual3,468US$11.12
04 Mar 24BuyUS$199,994Frazier Life Sciences Management, LPCompany21,052US$9.50
02 Jan 24SellUS$4,692Patrick BurnettIndividual1,325US$3.54

Insider Trading Volume

Insider Buying: ARQT insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of ARQT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,283,9831.71%
VC/PE Firms8,785,2846.58%
Hedge Funds21,688,18316.2%
Institutions100,713,35975.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24%.

Top Shareholders

Top 25 shareholders own 92.78% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.97%
Jennison Associates LLC
11,663,497US$174.8m0.79%0.09%
9.37%
Rubric Capital Management LP
10,966,672US$164.4m11.7%2.81%
9.16%
Suvretta Capital Management, LLC
10,721,511US$160.7m7.17%5.69%
7.71%
BlackRock, Inc.
9,029,556US$135.4m4.72%no data
7.51%
Frazier Life Sciences Management, LP
8,785,284US$131.7m0%4.85%
5.95%
The Vanguard Group, Inc.
6,962,635US$104.4m13.3%no data
5.88%
Polar Capital Holdings Plc
6,884,372US$103.2m0.08%0.35%
4.82%
State Street Global Advisors, Inc.
5,641,631US$84.6m9.87%no data
3.63%
Franklin Resources, Inc.
4,250,178US$63.7m-4.23%0.02%
3.21%
Morgan Stanley, Investment Banking and Brokerage Investments
3,759,286US$56.4m-4.57%0.01%
3.04%
Gilder Gagnon Howe & Co. LLC
3,553,838US$53.3m-1.73%0.54%
2.59%
Citadel Advisors LLC
3,031,073US$45.4m3.36%0.05%
2.11%
Geode Capital Management, LLC
2,470,138US$37.0m2.02%no data
2.06%
Ensign Peak Advisors, Inc.
2,416,812US$36.2m13.3%0.06%
1.99%
Cormorant Asset Management, LP
2,325,000US$34.9m-7.92%1.81%
1.81%
Pivotal BioVenture Partners LLC
2,120,508US$31.8m3.89%12.72%
1.52%
Medical Strategy GmbH, Asset Management Arm
1,779,301US$26.7m0%1.55%
1.52%
StemPoint Capital LP
1,778,318US$26.7m84.2%8.72%
1.49%
D. E. Shaw & Co., L.P.
1,745,024US$26.2m73.2%0.03%
1.36%
GW&K Investment Management, LLC
1,593,630US$23.9m-4.46%0.19%
1.27%
J. Goldman & Co., L.P.
1,492,217US$22.4m13.8%0.87%
1.25%
American Century Investment Management Inc
1,464,311US$22.0m18.9%0.01%
1.22%
Candriam, Société En Commandite Par Actions
1,426,496US$21.4m9.1%0.06%
1.17%
Goldman Sachs Group, Investment Banking and Securities Investments
1,370,123US$20.5m114%0.01%
1.16%
Perceptive Advisors LLC
1,358,500US$20.4m-12.8%0.45%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 14:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arcutis Biotherapeutics, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
Chris ShibutaniGoldman Sachs
Seamus FernandezGuggenheim Securities, LLC